Cargando…

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

BACKGROUND: Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments’ value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in breast cancer (BC),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Lauro, V., Barchiesi, G., Martorana, F., Zucchini, G., Muratore, M., Fontanella, C., Arpino, G., Del Mastro, L., Giuliano, M., Puglisi, F., De Laurentiis, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808450/ https://www.ncbi.nlm.nih.gov/pubmed/36399953 http://dx.doi.org/10.1016/j.esmoop.2022.100629

Ejemplares similares

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
por: Garutti, Mattia, et al.
Publicado: (2021)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
por: Pelizzari, Giacomo, et al.
Publicado: (2018)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
por: Di Maio, Massimo, et al.
Publicado: (2023)

Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications
por: De Placido, S, et al.
Publicado: (2017)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
por: Piezzo, Michela, et al.
Publicado: (2020)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
por: Gomes, Inês, et al.
Publicado: (2023)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
por: Sottotetti, Federico, et al.
Publicado: (2022)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Corrigendum to ‘Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review’: [ESMO Open Volume 6, Issue 5, October 2021, 100276]
por: Garutti, M., et al.
Publicado: (2021)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2017)

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
por: Garutti, M., et al.
Publicado: (2021)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole
por: Sini, V, et al.
Publicado: (2014)

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
por: Majumdar, Abir, et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
por: Ashai, Nadia, et al.
Publicado: (2023)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_epuk09knbqfjpsqdh7334ut65u